Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jan 25;6(2):359-367.
doi: 10.1182/bloodadvances.2021004441.

Epidemiology and treatment patterns of idiopathic multicentric Castleman disease in the era of IL-6-directed therapy

Sudipto Mukherjee  1 , Rabecka Martin  2 , Brenda Sande  2 , Jeremy S Paige  3 , David C Fajgenbaum  4
Affiliations

Epidemiology and treatment patterns of idiopathic multicentric Castleman disease in the era of IL-6-directed therapy

Sudipto Mukherjee et al. Blood Adv. .

Abstract

The epidemiology of human herpesvirus-8-negative/idiopathic multicentric Castleman disease (iMCD) remains incompletely understood. Prior epidemiologic studies of CD and iMCD have been hampered by difficulties in accurate case ascertainment resulting from a lack of uniform diagnostic criteria and a disease-specific International Classification of Diseases (ICD) code. In this study, we provide reliable estimates of CD and iMCD in the United States using a novel claims-based algorithm that includes a CD-specific ICD (10th revision) diagnosis code (D47.Z2) supported by the presence of ≥2 claims codes corresponding to the minor criteria from the international evidence-based diagnostic criteria for iMCD. We additionally analyzed the treatment classes and patterns in the clinical course of patients with iMCD. Using an administrative claims database of 30.7 million individuals enrolled between 1 January 2017 and 31 December 2018, we identified 254 patients with iMCD, with an estimated annual incidence and prevalence of 3.4 (95% confidence interval [CI], 1.4-9.2) and 6.9 (95% CI, 3.7-13.3) cases per million, respectively. Among patients with iMCD, 39% received corticosteroid monotherapy, 33.1% received no iMCD-directed treatment, and 9.8% received interleukin-6 (IL-6)-targeted therapy with tocilizumab or siltuximab. Siltuximab, which is the only US Food and Drug Administration-approved treatment and established first-line treatment recommendation, was used in only 8.7% of patients with iMCD. This study provides the most up-to-date understanding of the iMCD disease burden in the United States and identifies a major unmet treatment need for IL-6-directed therapy in this vulnerable cohort.

PubMed Disclaimer

Figures

None
Graphical abstract
Figure 1.
Figure 1.
Algorithm used to identify patients with iMCD in MarketScan database.
Figure 2.
Figure 2.
Treatment switching patterns in patients with iMCD. No treatment cohort refers to patients who had no claims for iMCD-directed treatments.
See this image and copyright information in PMC

References

    1. Yu L, Tu M, Cortes J, et al. . Clinical and pathological characteristics of HIV- and HHV-8-negative Castleman disease. Blood. 2017;129(12):1658-1668. - PMC - PubMed
    1. Dispenzieri A, Fajgenbaum DC. Overview of Castleman disease. Blood. 2020;135(16):1353-1364. - PubMed
    1. Fajgenbaum DC, Uldrick TS, Bagg A, et al. . International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease. Blood. 2017;129(12):1646-1657. - PMC - PubMed
    1. Munshi N, Mehra M, van de Velde H, Desai A, Potluri R, Vermeulen J. Use of a claims database to characterize and estimate the incidence rate for Castleman disease. Leuk Lymphoma. 2015;56(5):1252-1260. - PubMed
    1. Robinson D Jr, Reynolds M, Casper C, et al. . Clinical epidemiology and treatment patterns of patients with multicentric Castleman disease: results from two US treatment centres. Br J Haematol. 2014;165(1):39-48. - PubMed

Supplementary concepts